Phase 2 Study of Venetoclax Plus Rituximab or Randomized Ven Plus Bendamustine plus Rituximab (BR) Versus BR in Patients with Relapsed/Refractory Follicular Lymphoma: Interim Data

被引：8
|
作者：
Zinzani, Pier Luigi [1 ]
Topp, Max S. [2 ]
Yuen, Sam L. S. [3 ]
Rusconi, Chiara [4 ]
Fleury, Isabelle [5 ,6 ]
Pro, Barbara [7 ]
Gritti, Giuseppe [8 ]
Crump, Michael [9 ]
Hsu, Wanling [10 ]
Punnoose, Elizabeth A. [10 ]
Hilger, James [10 ]
Mobasher, Mehrdad [10 ]
Hiddermann, Wolfgang [11 ]
机构：
[1] Univ Bologna, Inst Hematol LEA Seragnoli, Bologna, Italy
[2] Univ Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany
[3] Calvary Mater Newcastle, Dept Haematol, Newcastle, NSW, Australia
[4] Osped Niguarda Ca Granda, Div Hematol, Milan, Italy
[5] Maisonneuve Rosemont Hosp, Dept Hematol, Montreal, PQ, Canada
[6] Univ Montreal, Montreal, PQ, Canada
[7] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA
[8] Osped Papa Giovanni XXIII, Hematol & BMT Unit, Bergamo, Italy
[9] Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada
[10] Genentech Inc, San Francisco, CA USA
[11] Klinikum Univ Munchen, Dept Internal Med 3, Munich, Germany
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.617.617
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
617
引用
收藏
页数：7
相关论文
共 50 条
  • [1] Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia - Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study
    Seymour, John F.
    Kipps, Thomas J.
    Eichhorst, Barbara F.
    Hillmen, Peter
    D'Rozario, James M.
    Assouline, Sarit
    Owen, Carolyn Jane
    Gerecitano, John
    Robak, Tadeusz
    De la Serna, Javier
    Jaeger, Ulrich
    Cartron, Guillaume
    Montillo, Marco
    Humerickhouse, Rod
    Punnoose, Elizabeth
    Li, Yan
    Boyer, Michelle
    Humphrey, Kathryn
    Mobasher, Mehrdad
    Kater, Arnon P.
    BLOOD, 2017, 130
  • [2] AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
    Leonard, John P.
    Trneny, Marek
    Izutsu, Koji
    Fowler, Nathan H.
    Hong, Xiaonan
    Zhu, Jun
    Zhang, Huilai
    Offner, Fritz
    Scheliga, Adriana
    Nowakowski, Grzegorz S.
    Pinto, Antonio
    Re, Francesca
    Fogliatto, Laura Maria
    Scheinberg, Phillip
    Flinn, Ian W.
    Moreira, Claudia
    Cabecadas, Jose
    Liu, David
    Kalambakas, Stacey
    Fustier, Pierre
    Wu, Chengqing
    Gribben, John G.
    Calaminici, Maria
    Copie-Bergman, Christiane
    Lopez-Guillermo, Armando
    O'Connor, Owen
    Williams, Michael
    Suciu, Stefan
    Levine, Benjamin
    Kern, Julie
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (14) : 1188 - +
  • [3] Bendamustine-120 plus rituximab therapy for relapsed or refractory follicular lymphoma: a multicenter phase II study
    R Sakai
    K Ohmachi
    F Sano
    R Watanabe
    H Takahashi
    H Takasaki
    M Tanaka
    Y Hattori
    H Kimura
    M Takimoto
    T Tachibana
    E Tanaka
    Y Ishii
    Y Ishiyama
    M Hagihara
    K Miyazaki
    K Yamamoto
    N Tomita
    K Ando
    Annals of Hematology, 2019, 98 : 2131 - 2138
  • [4] Bendamustine-120 plus rituximab therapy for relapsed or refractory follicular lymphoma: a multicenter phase II study
    Sakai, R.
    Ohmachi, K.
    Sano, F.
    Watanabe, R.
    Takahashi, H.
    Takasaki, H.
    Tanaka, M.
    Hattori, Y.
    Kimura, H.
    Takimoto, M.
    Tachibana, T.
    Tanaka, E.
    Ishii, Y.
    Ishiyama, Y.
    Hagihara, M.
    Miyazaki, K.
    Yamamoto, K.
    Tomita, N.
    Ando, K.
    ANNALS OF HEMATOLOGY, 2019, 98 (09) : 2131 - 2138
  • [5] Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study
    Flowers, Christopher R.
    Matasar, Matthew J.
    Herrera, Alex F.
    Hertzberg, Mark
    Assouline, Sarit
    Demeter, Judit
    Mcmillan, Andrew
    Mehta, Amitkumar
    Opat, Stephen
    Trneny, Marek
    Musick, Lisa
    Hirata, Jamie
    Yang, Annie
    Sehn, Laurie H.
    REVISTA CHILENA DE LITERATURA, 2024, (109): : 1194 - 1205
  • [6] Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study
    Flowers, Christopher R.
    Matasar, Matthew J.
    Herrera, Alex F.
    Hertzberg, Mark
    Assouline, Sarit
    Demeter, Judit
    Mcmillan, Andrew
    Mehta, Amitkumar
    Opat, Stephen
    Trneny, Marek
    Musick, Lisa
    Hirata, Jamie
    Yang, Annie
    Sehn, Laurie H.
    HAEMATOLOGICA, 2024, 109 (04) : 1194 - 1205
  • [7] Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia-Results From Pre-Planned Interim Analysis of the Randomized Phase 3 MURANO Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (01) : 12 - 14
  • [8] ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
    Ghia, Paolo
    Pluta, Andrzej
    Wach, Malgorzata
    Lysak, Daniel
    Kozak, Tomas
    Simkovic, Martin
    Kaplan, Polina
    Kraychok, Iryna
    Illes, Arpad
    de la Serna, Javier
    Dolan, Sean
    Campbell, Phillip
    Musuraca, Gerardo
    Jacob, Abraham
    Avery, Eric
    Lee, Jae Hoon
    Liang, Wei
    Patel, Priti
    Quah, Cheng
    Jurczak, Wojciech
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (25) : 2849 - +
  • [9] LENALIDOMIDE PLUS RITUXIMAB IN ELDERLY PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
    Della Cioppa, P.
    Lucania, A.
    Esposito, M.
    Improta, S.
    Mastrullo, L.
    HAEMATOLOGICA, 2015, 100 : 151 - 151
  • [10] COST-EFFECTIVENESS OF DUVELISIB VERSUS THE BENDAMUSTINE PLUS RITUXIMAB REGIMEN FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA PATIENTS IN CHINA
    Chen, L.
    Tan, B.
    Gao, X.
    Zhou, K.
    Zhao, J.
    Xuan, J.
    VALUE IN HEALTH, 2023, 26 (12) : S181 - S182
12345